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Introduction
Contrast enhancement has become a routine 
part of clinical radiography, computed tomogra-
phy (CT), and magnetic resonance imaging (MRI),
increasing their diagnostic capabilities. During the
last two decades, contrast-enhanced ultrasound
imaging has been investigated and has gradually
emerged in clinical settings. Concurrent with tech-
nological improvements in ultrasound scanning
equipment, contrast agents have been developed
to meet the demands of this rapidly expanding
field of imaging.
The rapid development of contrast agents for
ultrasound is precipitated by the performance lim-
its of ultrasound imaging and Doppler techniques.
As ultrasound is used to study smaller and deeper
structures in the body, the spatial resolution of
grayscale imaging and Doppler sensitivity becomes
impaired to the degree that it impacts the clinical
utility of ultrasound. Contrast agents promise to
improve the sensitivity and specificity of current
ultrasound diagnoses and have the potential to
expand the already broad range of ultrasound
applications. This article is intended to provide
an overview of the principles behind ultrasound
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contrast agents and a review of the clinical appli-
cations in which they are useful.
Types of Contrast Agents Available
During the last decade, many new ultrasound con-
trast agents have been developed, which are char-
acterized by both smaller microbubble mean size
(< 10 μm) and prolonged persistence within the
cardiovascular circulation (increased from less than
1 minute to as much as 10 minutes). Various tech-
niques are used to combine materials that control
the microbubble surface (the encapsulating shell)
with gases that inhibit diffusion and microbubble
dissolution (air vs. heavy gases such as perfluoro-
carbons). At present, several contrast agents have
been approved for clinical use while others are in
various stages of development (Table).
Basic Principles
Vascular ultrasound contrast agents consist of gas-
filled microbubbles stabilized by a thin shell (Fig. 1).
They are typically < 8 μm in diameter, which allows
them to pass through the pulmonary circulation
and systemic capillary beds [1]. When administered
intravenously, ultrasound contrast agents improve
the detection of blood flow and depiction of the
vasculature in a variety of structures compared to
conventional (i.e. non-contrast) ultrasound due to
increased signal-to-noise ratio (SNR). These agents
significantly enhance the acoustic backscatter from
blood in both Doppler and grayscale modes, due
to the large impedance difference between the gas
and the surrounding blood. Previous techniques
have used the enhancement of Doppler flow signals
(either color Doppler or power Doppler) to visualize
the presence of a contrast agent in the vessels or
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Table. fList o  ultrasound contrast agents
Name Shell composition Gas Manufacturer
AI-700 Polymer Perfluorocarbon Acusphere
biSphere Gelatin/polymer Air Point Biomedical
BR14 Phospholipid Perfluorobutane Bracco Diagnostics
BY 963 Lipid Air Byk-Gulden
Levovist Galactose/palmitic acid Air Schering
Definity Lipid Perfluoropropane Bristol-Myers Squibb
Imagent Surfactant Perfluorocarbon Imcor Pharmaceuticals
Optison Albumin Perfluoropropane GE Healthcare
Sonazoid Lipid Perfluorobutane GE Healthcare
SonoVue Surfactant SF6 Bracco Diagnostics
MRX-408 Lipid/ligand oligopeptide Perfluoropropane ImaRx
Quantison Albumin Air Andaris Ltd
QFX Albumin Perfluorocarbon Guangzhou Nanfang Hospital
iF g. 1. Microscopic view of microbubbles 2–8mm in size.
organs of interest. Due to artifacts associated with
color flow imaging (e.g. color blooming and poor
spatial resolution), this may not be an ideal method
of imaging with ultrasound contrast agents. In cer-
tain contrast-specific imaging modes, the SNR can
be further improved by suppression of tissue signals.
The improved SNR can also be exploited in non-
vascular structures like the urinary bladder, fallopian
tubes and lymphatic channels.
In order to better separate signals from tissue and
the contrast agent, tissue signal suppression has to
be carried out. This can be achieved by phase/pulse
cancellation, coded pulses or amplitude modulation.
Although there are different methods commercially
available with differing levels of sophistication and
technology, grayscale phase/pulse inversion is the
basis of most of the modes used for grayscale
imaging with ultrasound contrast agents [2,3].
This technique cancels first harmonic (linearly scat-
tered) signals by transmitting a pulse sequence
where each pulse is an inverted copy of the previ-
ous pulse, and then summing the echoes from
subsequent pulses (resulting in zero under linear
scattering conditions). Hence, echoes from station-
ary tissue will be suppressed. However, nonlinear
echoes arising from contrast microbubbles will not
cancel out and, thus, can be preferentially detected
and displayed.
Contrast-specific Imaging Technology
Conventional ultrasound systems have technical
limitations when used with ultrasound contrast
agents. These limitations can ultimately reduce the
usefulness of the contrast agent effects. Thus, ultra-
sound equipment has been and continues to be
modified to optimize their use with a variety of ultra-
sound contrast agents.
In general, during insonation, ultrasound contrast
agents produce a linear response at low acoustic
pressures (< 50 kPa), which means the microbub-
bles will undergo rhythmic oscillations at a reso-
nant frequency (f0). A nonlinear contrast agent
response occurs at intermediate pressures (from
approximately 50 to 500 kPa). This nonlinear
response consists of an asymmetric change in
microbubble size due to greater resistance to com-
pression than expansion, which produces harmonic
and subharmonic signal components (i.e. frequency
components at 2f0, 3f0, 4f0, etc., and at 1/2f0,, 1/3f0,
etc.) (Fig. 2) [4]. Eventually, at higher acoustic
pressures (> 500 kPa; although these pressure levels
vary significantly from agent to agent), the contrast
microbubbles will be disrupted and destroyed.
Harmonic Imaging
Harmonic imaging (HI) is one such modification
which was originally developed for contrast-
enhanced ultrasound imaging. The phenomenon of
harmonic generation is not confined to microbubble-
based contrast agents but can also be induced in
native tissue, and this forms the basis of native tis-
sue harmonic imaging (THI). HI uses the same
broadband transducers used for conventional imag-
ing, but the ultrasound system is configured to pri-
marily receive echoes at the second harmonic
frequency (i.e. twice the transmit frequency). HI
provides a way to better differentiate areas with and
without contrast microbubbles. Therefore, contrast-
enhanced HI has the potential to demonstrate, in
real-time, grayscale blood flow imaging (i.e. perfu-
sion imaging) (Fig. 3). The frequencies and para-
meters of wideband HI that are used depend on
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iF g. 2. f b bbl h h f dSpectrum o  a micro u e agent s owing t e un a-
mental (f = d2 MHz), second harmonic (HI at 4 MHz), an
subharmonic (SHI at 1 MHz) components.
the specific characteristics (i.e. microbubble size and
shell composition) of the ultrasound contrast agent
being utilized. Selection of the appropriate agent
and imaging mode allows optimization of the util-
ity of contrast-enhanced ultrasound imaging [5].
Initially, HI relied on simple filtering techniques
to extract the harmonic microbubble signals, but
more sophisticated processing schemes have
emerged over the recent years. Currently, the
mode with the best SNR and suppression of
unwanted tissue signal is wideband HI. Further
improvements are possible with the use of pulse
inversion HI [6–8]. Additional details on the equip-
ment and software available for ultrasound con-
trast imaging may be found in the recent EFSUMB
guideline paper [9].
Intermittent Imaging
In order to enhance detection of tumor neovas-
cularity with contrast agents, these agents must
traverse into these smaller vessels. Conventional
ultrasound systems, however, often deliver power
levels that are sufficient to destroy contrast micro-
bubbles, especially when using a high mechanical
index (MI). If the microbubbles are destroyed
before they reach the neovasculature, the desired
enhancement of flow in tumor vessels will not be
observed. A potential solution to this problem is
the use of intermittent ultrasound imaging, which
has been shown to increase ultrasound contrast
enhancement [10–12]. The degree of enhance-
ment with intermittent imaging is dependent upon
flow rate, acoustic power output and the frequency
of insonation [13]. With continuous grayscale
ultrasound imaging, contrast microbubbles within
the imaging plane may be destroyed during the
acquisition of each frame of the image. Since a
typical grayscale ultrasound image is refreshed at
30 frames per second, the available contrast agent
for each new image frame is that amount which
enters the imaging plane in 1/30th of a second. In
this short time between frames, contrast may enter
larger vessels, but will not generally reach the micro-
circulation. With intermittent imaging, the ultra-
sound beam is turned off for longer periods between
each image frame. More contrast microbubbles then
enter the imaging field during this interscan
period, resulting in increased echo-enhancement.
Furthermore, the contrast material will have time
to traverse further into the capillary bed.
Flash echo imaging is a particular combination
of regular and intermittent grayscale imaging tech-
niques, consisting of low power real-time monitor
pulses transmitted continuously, while microbubble
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BA
iF g. 3. rCompared with fundamental imaging (A), second harmonic imaging (B) of a kidney after contrast injections shows bette
enhancement and vascular definition.
destruction is achieved with intermittent higher
power flash pulses [14]. These two modes are dis-
played simultaneously in a dual screen format. Each
sequence of multiple-frame (1–15 frames) flash
pulses can be triggered manually or electronically
(e.g. every 1–8 seconds). The principle of micro-
bubble destruction in intermittent mode has been
used by investigators to measure mean myocardial
microbubble velocity and to assess the microvas-
cular cross-sectional area during constant infusion of
contrast [15]. The product of these two estimates
is the mean myocardial blood flow (i.e. a measure
of myocardial perfusion). To date, flash echo imag-
ing is the only quantitative method for ultrasound
perfusion estimation (in mL/min/g) that has been
developed.
Continuous Imaging
Although intermittent imaging can obtain high
contrast within a single frame, this imaging mode
is not real-time, which may impair the visualization
of some structures and the utility of the modality.
In the last few years, a number of other methods
have been introduced (some commercially), such as
pulse inversion HI, superharmonic imaging, power
harmonics, coded harmonic angio and agent detec-
tion imaging [16–21], which employ low acoustic
power settings and contrast-specific processing to
produce a real-time display of the region of interest.
The visualization of the enhancement pattern of
the normal and abnormal tissues can significantly
improve the diagnostic capability of ultrasound
imaging.
Other Imaging Methods
When imaging small vessels or if the concentration of
contrast is low, the echogenicity of contrast micro-
bubbles can be limited. However, collecting images
over an extended period of time (e.g. 3–10 sec-
onds) using alternative post-processing techniques
(e.g. maximum intensity projection) can achieve a
temporally summed (or compounded) enhanced
image. This is the basis of a commercially available
technique [3], which has currently been imple-
mented by three manufacturers (Fig. 4).
Under specific conditions, gas microbubbles gen-
erate subharmonics, which occur mainly at half the
transmitted frequency. Compared to superharmonic
imaging, an advantage of subharmonic imaging is
that tissue signal is minimal, which results in a high
agent-to-tissue ratio (i.e. high SNR). Reports have
described the feasibility and implementation of
subharmonic ultrasound imaging [22,23] (Fig. 5).
Currently, subharmonic ultrasound imaging is still in
its early development.
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iF g. 4. Contrast-enhanced imaging using micro-flow imaging
dmode shows a high resolution depiction of normally perfuse
kidney parenchyma in an animal model.
iF g. 5. Subharmonic image of a canine kidney shows the per-
fusion pattern of vasculature of the kidney with suppression of
background tissue.
Clinical Applications
Clinical applications for ultrasound contrast agents
can potentially be found in any structure that is eval-
uated with conventional ultrasound, with the only
exception being the fetus. The major applications of
ultrasound contrast agents are in cardiac and hepatic
imaging. Other applications are being explored,
although there are currently fewer reports on their
clinical use. The assessment of vascularity by demon-
stration of microvessels or increased parenchymal
signal intensity provides a new parameter in diag-
nostic evaluation, just like intravenous contrast has
enhanced CT and MRI as well as nuclear imaging.
Hepatic uses
The use of ultrasound contrast agents for evalua-
tion of the liver has become widespread and can
be considered routine in parts of Europe and Asia
[4]. Current microbubble-based agents are essen-
tially blood pool agents. The type of enhancement
demonstrated in the liver is similar to that shown
with contrast-enhanced CT and MRI. Therefore,
interpretation of the enhancement patterns in
contrast-enhanced ultrasound is similar to those
performed with contrast-enhanced CT or MRI. In
addition, continuous scanning at low acoustic pres-
sures may reveal dynamic contrast enhancement
that can be quite helpful for characterization of a
variety of focal liver lesions (Fig. 6).
Hepatic pathology can be considered in two
main groups: focal lesions and diffuse disease. The
characteristic patterns of enhancement in benign
and malignant liver lesions have been described [24].
There is good concordance with the enhancement
characteristics of focal liver lesions using contrast-
enhanced ultrasound with those that have been
described for CT and MRI studies [25,26]. This is true
for benign and malignant hepatic tumors [27]. There
is better characterization of certain focal lesions
like hepatocellular carcinoma (HCC) and metastatic
lesions (Fig. 7) compared to an unenhanced ultra-
sound scan [28]. This is especially the case for small
(< 2 cm) focal liver lesions. Contrast agents have
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C
iF g. 6. r (A) Baseline imaging shows a heterogeneous live
mass (T). (B) Following a bolus injection of Sonovue (Bracco,
tMilan, Italy), characteristic peripheral globular enhancemen
of the tumor (T) is present. (C) After several minutes, cen-
ttripetal filling of the tumor (T) is observed. This enhancemen
pattern is consistent with a hemangioma.
been shown to be useful in improving the detec-
tion of HCC (Fig. 8), in differentiating HCC from
regenerating nodules and to detect recurrence in
treated lesions. Complementary information may
be obtained when compared to contrast-enhanced
CT scans [29]. This improvement shows good inter-
observer concordance [30]. Focal nodular hyper-
plasia has a central star-like pattern of enhancement
that can be observed with continuous contrast-
enhanced ultrasound (Fig. 9) [31]. Due to the tran-
sient nature of enhancement, the star-like pattern
may not be seen in all examinations, especially if
an intermittent mode is used.
In some cases, there is overlap of the benign
and malignant features in focal liver lesions on
contrast-enhanced ultrasound, but the use of addi-
tional parameters may provide advantages over
CT and MRI. For example, hepatic transit time has
been found to be useful in monitoring post
radiofrequency (RF) ablation procedures [32] and
contrast-enhanced power Doppler imaging for
radiotherapy [33]. For diffuse liver disease like cir-
rhosis, global parameters such as hepatic transit
time show promise in being able to diagnose cir-
rhosis without biopsy. A prospective study that
assessed the diagnostic accuracy of transhepatic
circulatory time with an ultrasound contrast agent
demonstrated that the hepatic artery to hepatic
vein and portal vein to hepatic vein interval times
were significantly shorter in the cirrhosis group
Contrast-enhanced Ultrasound
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iF g. 7. (A) Conventional grayscale imaging shows suspicious masses within a heterogeneous liver in a patient with colon cancer.
(B) Contrast-enhanced pulse inversion harmonic imaging improved the delineation of multilobulated tumors (T) within the
enhanced liver parenchyma.
A B
iF g. 8. t(A) Harmonic imaging of a hepatocellular carcinoma demonstrates tumor (T) enhancement in its arterial phase using Agen
Detection Imaging mode (ADI; Siemens, Issaquah, WA, USA). (B) In its delayed phase, the tumor (T) appears as a hypoechoic lesion
within the contrast-enhanced parenchyma.
(7.4 ± 1.7 s and 1.9 ± 1.5 s, respectively) compared
with those in the noncirrhosis group (normal: 15.6 ±
2.1 s and 11.1 ± 1.7 s, p < 0.001 and p < 0.001; and
hepatitis: 12.8 ± 4.1 s and 7.8 ± 4.4 s, p < 0.001
and p < 0.002, respectively) [34]. Hepatic transit
time can also distinguish between cirrhosis and
severe hepatitis from mild hepatitis, although there
is overlap between severe hepatitis and cirrhosis.
Interventional and intraoperative uses
The ablation of lesions with RF is a technique that
is increasing in popularity, especially in the treat-
ment of unresectable liver lesions. The ideal method
of monitoring ablation during the procedure itself
and in post-ablation follow-up has not been estab-
lished. Contrast-enhanced ultrasound has been used
in diagnosis of lesions before ablation as well as
monitoring the outcome of ablation procedures in
the liver (Fig. 10) [35].
Contrast-enhanced ultrasound has the potential
to be very useful as it allows real-time assessment
of lesion vascularity [36] and is similar to dynamic
CT in its sensitivity and specificity [37,38]. Grayscale
pulse inversion HI is superior to power Doppler
contrast-enhanced ultrasound [39], and both are
superior to conventional ultrasound [40] in demon-
strating residual tumor after thermal ablation. Similar
findings have been described in a preliminary
report on ablation of renal lesions [41]. The use of
contrast-enhanced ultrasound for intraoperative
evaluation of focal liver lesions should promise to
improve detection of sub-centimeter nodules, show
nodular vascularity with greater detail, and poten-
tially improve clinical outcomes [42].
Contrast-enhanced ultrasound imaging has been
used to delineate thermal lesions from viable tissue
during RF ablation of the prostate in an animal
model. The initial results demonstrated that contrast-
enhanced imaging is able to guide and monitor the
RF ablation of the entire prostate (Fig. 11). This tech-
nique holds a great potential for future use in humans
as an innovative treatment of prostate cancer [43].
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iF g. 9. (A) Conventional grayscale imaging shows an isoechoic lesion (T) in the right lobe of the liver. (B) After a bolus injection of tcontras
agent, the tumor demonstrates a central star-like pattern of enhancement, consistent with a diagnosis of focal nodular hyperplasia.
iF g. 10. rPulse inversion harmonic imaging of a liver tumo
post radiofrequency ablation demonstrates a small residual
viable nodule (arrows) at the periphery of the lesion.
Echocardiographic uses
In the United States and Europe, the Food and Drug
Administration (FDA) and the European Union
have approved several contrast agents for use during
echocardiography examinations with the specific
indication of providing ventricular opacification
and enhancement of endocardial border definition
in patients with technically suboptimal echocar-
diograms (Fig. 12). Contrast echocardiography
includes applications for the right ventricle such as
demonstration of shunts, abnormalities in the posi-
tion or presence of the great vessels, and for the left
ventricle such as cardiac structure, valvular function
and wall motion. Additional applications include
perfusion quantification and reperfusion assessment
of the myocardium [44,45].
The administration of contrast agents has been
shown to enable more accurate measurement of
left ventricular volume, ejection fraction, diagnosis
and grading of valvular disease, intracardiac throm-
bus detection, aortic dissection, detection of compli-
cations of myocardial infarction (such as ventricular
rupture and aneurysm formation), and improved
assessment of systolic function compared to con-
ventional ultrasound imaging. In stress echocar-
diography, contrast agents increase the number of
interpretable segments, which allows accurate assess-
ment of left ventricular function [46]. At the myocar-
dial level, contrast agents can be used to diagnose
Contrast-enhanced Ultrasound
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B
iF g. 11. c(A) Contrast-enhanced pulse inversion harmoni
imaging of a canine prostate after radiofrequency ablation
identifies a demarcated thermal lesion (L) within contrast-
perfused normal parenchyma. This information is useful for
monitoring radiofrequency ablation of the entire prostate. 
(B) Pathologic specimen showing the coagulated lesion corre-
sponding to the ultrasound findings.
A B
iF g. 12. (A) Suboptimal echocardiography of the left ventricle (LV) shows inadequate endocardial border definition. (B) After intra-
venous contrast injection, complete opacification of the left ventricle (LV) is obtained and the endocardial borders are clearly seen.
infarction and assess tissue viability. Coronary artery
stenoses can be localized and their severity quantified
using contrast-enhanced intermittent HI. Coronary
perfusion rates may be calculated using microbub-
ble destruction and reperfusion techniques [47].
Cerebrovascular uses
Significant limitations exist in current transcranial
Doppler ultrasound examinations. These include low
reproducibility, inter-investigator variability, and
inadequate access through the skull. Thus, transcra-
nial Doppler examinations can be improved with the
use of ultrasound contrast agents [48]. Ultrasound
contrast agents provide better delineation of normal
blood flow, occlusions, pseudo-occlusions, stenoses,
and collaterals in the extracranial and intracranial
vascular beds [49]. For examination of the extracra-
nial carotid arteries, contrast administration can
increase visualization of the residual lumen, increase
diagnostic confidence, and decrease the number of
indeterminate examinations. However, the appli-
cations of contrast agents to the carotid artery are in
their infancy. Clinical trials are necessary to deter-
mine optimal techniques for contrast-assisted carotid
imaging.
Thyroid and parathyroid uses
Ultrasound contrast agents have been used to obtain
time-intensity curves of flow through thyroid nod-
ules. This has the potential to differentiate between
benign and malignant lesions and to characterize
hypovascularized malignant nodules that could not
be observed without contrast [50]. A more rapid
time to peak signal intensity has been documented
in malignant thyroid nodules [51]. In parathyroid
lesions that do not show flow with conventional
ultrasound, contrast agents can provide useful infor-
mation by visualizing typical color Doppler signals
of the parathyroid lesions. This can help to distin-
guish parathyroid nodules from thyroid lesions [52].
Gastrointestinal uses
Contrast-enhanced ultrasound has been used to
evaluate patients with portal hypertension by
enhancing the Doppler signal and permitting
better visualization of esophageal varices transab-
dominally [53] and perforating veins in recurrent
varices [54]. This technique has great potential for
improving early detection of visceral varices and
monitoring of therapeutic response.
Bowel pathology may be diagnosed on the
basis of altered vascularity. Ultrasound contrast
agent can demonstrate ischemia [55] and help dif-
ferentiate benign from malignant gastrointestinal
stromal tumors [56]. Assessment of inflammatory
bowel disease can also be improved with the use
of contrast agents by demonstrating increased
vascularity in affected segments [57]. This is of
benefit in determining if active disease is present
or only fibrosis even when the bowel wall does not
show significant thickening [58]. The same reason-
ing applies in the evaluation of pathologic hyper-
emic bowel, e.g. in acute appendicitis [59].
The use of orally administered ultrasound con-
trast agents for bowel evaluation has also been
shown to be of value [60]. Oral contrast agents
appear to significantly improve the ability to
image both normal and abnormal structures in the
gastrointestinal tract (Figs. 13 and 14), and to pro-
vide an acoustic window for evaluation of adjacent
organs such as the pancreas (Fig. 15). Acoustic
artifacts associated with bowel gas often prevent
complete ultrasonic evaluation of the pancreas,
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iF g. 13. dFollowing the ingestion of oral contrast, ultrasoun
imaging shows a uniform and homogeneous echogenicity within
the stomach (ST). Note that a demarcated defect on the poste-
rior wall of the stomach is clearly seen, which corresponds to an
ulceration lesion.
which has led to CT being the primary choice for
the evaluation of this organ. Evaluation of oral
ultrasound contrast agents has shown significant
improvement in visualization of the stomach, pan-
creas and adjacent structures. These oral agents
could be coupled in the future with an intravenous
contrast agent, enhancing the ability of ultrasound
to detect pancreatic tumors.
Gallbladder and biliary tree uses
There are a few published reports that describe the
use of ultrasound contrast agents for the evaluation
of abnormalities of the gallbladder and biliary tree.
One report described how the detection and staging
of malignant hilar obstructions of the biliary tree
was improved by the use of Levovist in the post-
vascular phase of sonography compared with con-
ventional sonography [61]. Some studies described
how ultrasound contrast agents can increase visual-
ization of the vasculature in the gallbladder wall and
hyperemia of the liver parenchyma adjacent to the
gallbladder in cases of acute cholecystitis [62,63].
Renal uses
Contrast-enhanced ultrasound of the kidney can
provide a clear and detailed view of renal vascular-
ity, with early enhancement in the arterial phase
followed by an intense and uniform enhancement
in the renal cortex (i.e. perfusion imaging). The
enhancement then extends to the pyramids until
they become isoechoic with the cortex.
The application of ultrasound contrast agents
in the characterization of renal tumors has great
promise. Contrast-enhanced ultrasound has the
potential to perform dynamic time-contrast inten-
sity curves [64], characterize focal renal lesions [65],
evaluate for the presence of a pseudocapsule in
renal cell carcinoma [66], and evaluate the collecting
system for vesicoureteric reflux [67]. Other potential
renal applications for contrast imaging include the
evaluation of renal perfusion, kidney transplants,
and monitoring tumor ablation procedures.
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iF g. 14. Transverse ultrasound imaging of the stomach (ST)
after ingestion of oral contrast shows irregular thickening of the
twalls of the pylorus with a narrowed gastric cavity, consisten
with gastric cancer in the pyloric region.
A B
iF g. 15. (A) Pre-contrast transverse imaging of the mid epigastrium reveals partial obscuration of the head of the pancreas. 
(B) Post-contrast imaging shows a hypoechoic mass (M) at the head of the pancreas through a contrast-filled stomach (ST).
Dilation of the pancreatic duct is also seen.
Prostate uses
In order to more accurately detect the presence of
prostate cancer, researchers have focused upon the
detection of neovascularity in prostate cancer. The
vascular supply to malignant prostate tissue differs
from the vascularity of normal prostate tissue in den-
sity and distribution of microvessels. Studies of the
prostate demonstrate a clear association of increased
microvessel density with the presence of cancer [68].
Quantitative assessment of microvascular density
may actually provide important data to guide ther-
apeutic decisions [69]. Unfortunately, the microves-
sels that proliferate around and within prostate
cancers are below the limits of the resolution of
conventional Doppler ultrasound.
One potential solution to this problem may
be the use of ultrasound contrast agents to 
detect flow in microvessels associated with cancer.
An early study suggested that contrast-enhanced
color flow detection of increased vascularity was
associated with the presence of prostate cancer
[70]. Several additional studies have demonstrated
Doppler enhancement of vessels in prostate cancer
[71,72]. These preliminary studies suggested that
contrast agents might be useful in ultrasound
evaluation of prostate vascularity and improve
the detection of cancer (Fig. 16). Both contrast-
enhanced color Doppler and harmonic grayscale
imaging have been used successfully to improve
imaging of prostate cancer and to guide targeted
biopsy for definitive diagnosis of prostate cancer
[73–77].
Pancreatic uses
The pancreas may be evaluated with contrast-
enhanced ultrasound via a transabdominal approach
or endoscopically [78]. Preliminary reports show 
that contrast-enhanced ultrasound improves the con-
spicuity of pancreatic carcinoma compared to con-
ventional ultrasound [79,80]. Quantitative analysis of
the amount of post-contrast enhancement may be
useful in separating benign and malignant pancreatic
lesions [81]. Further work is needed to validate these
early findings.
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iF g. 16. (A) Baseline conventional ultrasound imaging of the
prostate reveals no evidence of abnormality. (B) Contrast-
enhanced real-time pulse inversion harmonic imaging shows an
enhanced focal area (M) compared with the rest of the gland.
(C) With intermittent imaging mode, the enhanced area is more
dramatically seen. Pathology proved this hypervascular area to
be prostate cancer.
Vascular uses
Preliminary reports have described how contrast-
enhanced ultrasound of the renal arteries can
improve visualization of the renal arteries and its
branches, improve the detection of renal artery
stenosis, reduce the duration of an examination
and improve the accuracy of these examinations
[82,83]. Improved detection of intra- and extrarenal
arteries with contrast-enhanced color Doppler
imaging provides a superior roadmap of the vessels
themselves and allows for more accurate placement
of the spectral Doppler sample volume. Several
clinical contrast studies in the evaluation of renal
artery stenosis (RAS) have produced encouraging
results [82,83]. In a multicenter trial, 191 patients
referred for renal arteriography were examined
with contrast-enhanced ultrasound. The ability to
image the renal arteries improved from 75% to 90%
after contrast administration (p < 0.001). Accuracy
in diagnosing RAS > 50% increased from 65% on
non-contrast evaluations to 78% with the use of
contrast [84,85].
Trauma uses
Traumatic lesions have common enhancement
features on cross-sectional imaging, independent
of the organ and tissues involved. The arterial tree
is invariably involved in all organs and contrast-
enhanced ultrasound easily detects parenchymal
lesions, such as lacerations and hematomas, pro-
viding detailed information on them [86]. The
findings were consistent with those of CT exams,
suggesting that contrast-enhanced ultrasound could
be a reliable technique for the evaluation of post-
traumatic parenchymal damage.
In the evaluation of trauma to the abdomen,
contrast-enhanced ultrasound has the advantage of
demonstrating viable tissue and improving contrast
between traumatic lesions and remaining normal
parenchyma. Although superior to conventional
ultrasound [87], contrast-enhanced ultrasound is
not yet a replacement for contrast-enhanced CT
[88]. However, contrast-enhanced ultrasound has
several advantages over CT, including the ability to
be performed at bed-side within the intensive care
unit and to be used for serial evaluations to deter-
mine if active bleeding is present. Thus, additional
research in this area is warranted.
Lymphatic uses
Microbubble-based ultrasound contrast agents
have been injected subcutaneously to enhance
detection of lymphatic channels (LCs) and sentinel
lymph nodes (SLNs) [89,90]. Clinically, SLN map-
ping is important for tumor staging (such as
breast, skin, and gastrointestinal tumors) and to
determine the use of adjuvant therapies. With 
traditional methods (e.g. lymphoscintigraphy or
injection of blue dyes and surgical dissection), it is
impossible to demonstrate the internal architecture
of the SLN, which is important for the detection of
metastatic spread to SLNs (initial accuracy 86%).
Contrast-enhanced lymphosonography is a mini-
mally-invasive technique to localize draining LCs
and SLNs (Fig. 17) and has the ability to evaluate
SLNs for metastases (Fig. 18). This new technique
also has the potential to enhance ultrasound-guided
biopsies of SLNs for improved tissue sampling for
definitive pathologic assessments.
Gene and Drug Delivery and
Targeted Agents
Functional ultrasound imaging of specific tissues
using targeted microbubbles represents a new
approach that departs from the concept that
Contrast-enhanced Ultrasound
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iF g. 17. Following subcutaneous injection of contrast agent in
an animal model, pulse inversion harmonic imaging identifies a
lcontrast-filled lymphatic channel (LC; arrows) and its sentine
lymph node (SLN).
microbubbles passively transit the microcirculation
like red blood cells. Targeted ultrasound imaging
involves the design and synthesis of microbubbles
that will adhere to endothelium or other targets
under disease-specific conditions (e.g. inflamma-
tion). To the extent that the microbubbles are
designed to adhere to molecular epitopes on the
surface of abnormal endothelium, targeted con-
trast imaging could provide capabilities for in vivo
ultrasonic detection of phenotypic features of
endothelium that predate clinical disease and/or
are otherwise not detectable using currently avail-
able technologies [91–93]. Investigators have
demonstrated that microbubbles can be phagocy-
tosed intact by activated neutrophils and mono-
cytes and can be detected by ultrasound imaging.
These findings indicate that contrast-enhanced
ultrasound may provide a useful means for the
noninvasive assessment of inflammation and to
follow the response to treatment [94].
Targeted imaging using contrast microbubbles
has advantages over other molecular imaging
methods. Unlike nuclear imaging approaches, ultra-
sound contrast microbubbles stay within the vas-
cular space and have a short circulation time. This
is useful to the extent that the technique is not
susceptible to nonspecific signals resulting from
extravasation of the imaging agent or retention in
non-target organs such as the liver. However, these
features are intrinsically limited to the interrogation
of phenomena occurring on the surface of endothe-
lial cells, thus excluding its application to many
important physiologic processes that occur intracel-
lularly and outside of the vascular space, for example,
gene therapy. Recent reports of acoustically active
nanoparticle emulsions (or gas-filled nanobubbles)
capable of exiting the vascular space may offer an
exciting solution to this challenge [95].
Targeted microbubbles may ultimately have
utility beyond their diagnostic attributes. Ultrasonic
destruction of microbubbles appears to enhance
delivery of genes, drugs, and lysis of clots (Fig. 19)
[96,97]. The ability to target therapeutics by design-
ing the delivery agent (microbubble) to be able
to reach the site of interest may ultimately prove
to be another powerful clinical application of this
exciting technology.
Summary
In conclusion, present and future ultrasound con-
trast agents should provide for increased diagnos-
tic capabilities in a variety of normal and abnormal
vascular applications. These agents will enhance
tumor vascularity, delineate areas of ischemia, and
improve visualization of many abnormalities, includ-
ing the detection and characterization of tumors in
such organs as the liver. Ultrasound contrast agents
that are non-toxic, intravenously injectable, and
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iF g. 18. In a swine melanoma model, contrast-enhanced ultra-
sound imaging identifies a metastatic sentinel lymph node (N),
which appears as partially enhanced normal lymphatic tissue
and hypoechoic tumor deposits (T). iF g. 19. rDiagram showing a targeted contrast agent used fo
thrombolysis.
stable for recirculation are already being used rou-
tinely in a variety of clinical applications. Future
developments including the continued modifica-
tion of ultrasound equipment to better exploit the
enhancement properties of contrast agents should
increase the capability of these agents to improve
the sensitivity and specificity of ultrasound imag-
ing. The field of targeted ultrasound imaging is still
in its infancy, and as with the field of molecular
imaging in general, much remains to be done to
develop this area into a clinical reality.
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